Shares of Graybug Vision, Inc. (NASDAQ:GRAY) were up 6.1% during trading on Thursday . The company traded as high as $13.51 and last traded at $13.48. Approximately 226,144 shares were traded during trading, an increase of 1% from the average daily volume of 223,511 shares. The stock had previously closed at $12.71.
In related news, Director Christy L. Shaffer purchased 18,750 shares of Graybug Vision stock in a transaction that occurred on Tuesday, September 29th. The stock was purchased at an average cost of $16.00 per share, with a total value of $300,000.00.
About Graybug Vision (NASDAQ:GRAY)
Graybug Vision, Inc, a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Recommended Story: Futures Contract
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.